Journal article

Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

ACJ van Akkooi, TJ Hieken, EM Burton, C Ariyan, PA Ascierto, SVMA Asero, CU Blank, MS Block, GM Boland, C Caraco, S Chng, BS Davidson, JP Duprat Neto, MB Faries, JE Gershenwald, DJ Grunhagen, DE Gyorki, D Han, AJ Hayes, WJ van Houdt Show all

Annals of Surgical Oncology | Published : 2022

Abstract

Exciting advances in melanoma systemic therapies have presented the opportunity for surgical oncologists and their multidisciplinary colleagues to test the neoadjuvant systemic treatment approach in high-risk, resectable metastatic melanomas. Here we describe the state of the science of neoadjuvant systemic therapy (NAST) for melanoma, focusing on the surgical aspects and the key role of the surgical oncologist in this treatment paradigm. This paper summarizes the past decade of developments in melanoma treatment and the current evidence for NAST in stage III melanoma specifically. Issues of surgical relevance are discussed, including the risk of progression on NAST prior to surgery. Technic..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Australian National Health and Medical Research Council (NHMRC) Program Grant


Awarded by NHMRC Practitioner Fellowship


Funding Acknowledgements

RAS and JFT are recipients of an Australian National Health and Medical Research Council (NHMRC) Program Grant (APP1093017), and RAS is supported by an NHMRC Practitioner Fellowship (APP1141295). RPMS is supported by the Melanoma Institute Australia. GVL is supported by an NHMRC Practitioner Fellowship and The University of Sydney Medical Foundation.